Novartis: 2010 results in line with forecasts
( Les Echos online – 27/01/2011 , The Financial Times online – 27/01/2011 )
For 2010, Novartis delivered results in line with forecasts. Profit rose 18% to $9.97bn versus $9.72bn expected. Turnover increased by 14% to 50.6 billion, in line with the estimated 50.54. Pharmaceutical sector sales decreased by 7% to $30.56bn. In the 4th quarter, net income fell by 2% to $2.27bn, turnover increased by 10% to $14.2bn and pharmaceutical division sales reached $8.03bn, +10%.
AstraZeneca: 4th quarter 2010 better than expected
( Les Echos online – 27/01/2011 )
AstraZeneca recorded quarterly results higher than expected, thanks also to the good performance of the anti-cholesterol Crestor (rosuvastatin). The turnover, in the 4th quarter of 2010, reached 8.62 billion dollars compared to the expected 8.38. Earnings per share were $1.39 per share, up 1%.
FY2010 slowdown for J&J
( The Financial Times online – 01/25/2011 , The New York Times online – 01/25/2011 , The Wall Street Journal online – 01/25/2011 , The New York Times Pag.B2 – 01/26/2011 , Finance & Markets Pag.10 – 26/01/2011 , The Wall Street Journal Europe Pag.21 – 26/01/2011 , Il Sole 24 Ore Finance & Markets Pag.38 – 26/01/2011 , MF- Milano Finanza Pag. .5 – 26/01/2011 , The Financial Times Pag.26 – 26/01/2011 , Les Echos online – 26/01/2011 )
Recent market recalls of certain products, mainly for children, have impacted Johnson & Johnson's 4th quarter 2010 accounts. Profits decreased by 12% to 1.9 billion dollars, compared to the 2.2 recorded in 2009 mainly due to the drop in sales (-8.1%) in the USA. For the full year 2010, J&J reported earnings growth of 8.7% to $13.3B and revenues decline of 0.5% to $61.6B. On Wall Street the
